- Trials with a EudraCT protocol (118)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
118 result(s) found for: Quetiapine.
Displaying page 1 of 6.
| EudraCT Number: 2006-002342-11 | Sponsor Protocol Number: D1449L00033 | Start Date*: 2007-04-19 |
| Sponsor Name:Klinikum Fulda gAG | ||
| Full Title: Multicenter study of neurotransmitters and neuropeptides in schizophrenia: A multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffer... | ||
| Medical condition: Patients have to fulfill the diagnostic criteria of a schizophrenia according to DSM-IV. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004681-33 | Sponsor Protocol Number: D1447C00001 | Start Date*: 2005-04-15 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600... | ||
| Medical condition: Bipolar Depression | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: LT (Completed) LV (Completed) EE (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-001195-21 | Sponsor Protocol Number: D1448C00015 | Start Date*: 2006-08-01 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Multicenter, Double-blind, Randomised, Parallel Group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-therapy in the... | ||
| Medical condition: Generalised Anxiety Disorder | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: EE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-005053-22 | Sponsor Protocol Number: D1448C00007 | Start Date*: 2006-03-30 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination with ... | ||
| Medical condition: Major Depressive Disorder (MDD). | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) FI (Completed) DE (Completed) CZ (Completed) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-001196-38 | Sponsor Protocol Number: D1448C00014 | Start Date*: 2006-06-14 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono-Therapy in t... | ||
| Medical condition: Major Depressive Disorder (MDD) | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) EE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-005812-25 | Sponsor Protocol Number: R076477BIM3002 | Start Date*: 2006-03-07 |
| Sponsor Name:Janssen-Cilag International N.V. | ||
| Full Title: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared with Flexi... | ||
| Medical condition: Bipolar I Disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: LT (Completed) GR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-005054-46 | Sponsor Protocol Number: D1448C00011 | Start Date*: 2006-03-17 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR... | ||
| Medical condition: Generalised Anxiety Disorder (GAD) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) FI (Completed) ES (Completed) DK (Completed) DE (Completed) SK (Completed) CZ (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-003745-14 | Sponsor Protocol Number: D1448C00005 | Start Date*: 2006-01-13 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Multi-centre, Double-blind, Randomised Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Monothe... | ||
| Medical condition: Maintenance treatment of patients with Major Depressive Disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) FI (Completed) SK (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-003519-33 | Sponsor Protocol Number: D1443L00003 | Start Date*: 2007-01-25 |
| Sponsor Name:AstraZeneca UK Limited | ||
| Full Title: RAPID - An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immedicate Release), over 14 days, in Acute Schizophrenia / Schizoaffecti... | ||
| Medical condition: Acute Schizophrenia and Schizoaffective Disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-006151-20 | Sponsor Protocol Number: D1449L00029 | Start Date*: 2006-08-29 | |||||||||||
| Sponsor Name:University of Erlangen-Nuremberg | |||||||||||||
| Full Title: Quetiapine and the dopaminergic epigenetic control – a pilot study | |||||||||||||
| Medical condition: Patients suffering from schizophrenia (ICD10: F20.x) Healthy controls | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-000479-40 | Sponsor Protocol Number: D1449L00030 | Start Date*: 2007-09-12 |
| Sponsor Name:Department of Psychiatry, RWTH Aachen | ||
| Full Title: Effects of quetiapine on ultrastructural hippocampal and neurochemical changes in patients with bipolar disorder: searching for the antidepressant and mood stabilising neurophysiology | ||
| Medical condition: Bipolar disorder is a common psychiatric disorder which is characterised by manic and depressive states. The mood stabilizing effect of novel antipsychotics seems to be modulation of neuronal plast... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001371-30 | Sponsor Protocol Number: D1443L00051 | Start Date*: 2009-02-16 |
| Sponsor Name:Universitätsklinikum Münster | ||
| Full Title: Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia | ||
| Medical condition: simple phobia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-000211-99 | Sponsor Protocol Number: D1449L00010 | Start Date*: 2005-04-12 |
| Sponsor Name:AstraZeneca A/S | ||
| Full Title: Acutely Manic Patients Insufficiently Responding After 2 Weeks Continued Quetiapine Monotherapy: Continued Quetiapine Versus Sodium Valproate Add-on. | ||
| Medical condition: Bipolar affective disorder | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-000088-12 | Sponsor Protocol Number: D1443C00012 | Start Date*: 2008-08-18 |
| Sponsor Name:Department of Psychiatry, LMU Munich | ||
| Full Title: A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3) | ||
| Medical condition: 40 patients with Acute Stress Disorder will be recruited within 2 years. The subjects must meet DSM- IV criteria for acute stress disorder (no acute suicidality) and will be treated with Quetiapine... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000912-13 | Sponsor Protocol Number: D1444C00146 | Start Date*: 2004-09-30 |
| Sponsor Name:AstraZeneca R&D Södertälje | ||
| Full Title: A 6-week International, Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study to Evaluate the Feasibility of Switching from Immediate-release Quetiapine Fumarate (SEROQUEL) to Sust... | ||
| Medical condition: Schizophrenia | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FI (Completed) HU (Completed) LT (Completed) ES (Completed) EE (Completed) LV (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001069-32 | Sponsor Protocol Number: D1449L0001 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Psychosis Early Detection and Intervention Centre, Department for Psychiatry, UKE Hamburg | ||
| Full Title: A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years | ||
| Medical condition: A prospective 8 weeks acute phase study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-005055-18 | Sponsor Protocol Number: D1448C00012 | Start Date*: 2006-05-18 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Multi-centre, Double-blind, Randomised-Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Monothe... | ||
| Medical condition: Maintenance treatment of patients with Generalised Anxiety Disorder. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) FI (Completed) HU (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-000041-60 | Sponsor Protocol Number: D1443L00040 | Start Date*: 2008-06-17 | |||||||||||
| Sponsor Name:LWL Universitätsklinik für Psychiatrie Bochum | |||||||||||||
| Full Title: Quetiapine in the treatment of psychotic depression. A pilot study (QTP-Dep-Bo) | |||||||||||||
| Medical condition: The planned open and monocentric trial investigates quetiapine as a monotherapy for patients with unipolar depression and psychotic features. The aim of this pilot study is to investigate the antid... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-005072-32 | Sponsor Protocol Number: R&D2004/39 | Start Date*: 2005-12-19 |
| Sponsor Name:Kings College London (IOP) / South London and Maudsley NHS Trust (Co-sponsorship) | ||
| Full Title: Is it possible to modify the course of manic relapse? A pilot study of the effectiveness of quetiapine in preventing the development of manic episodes in Bipolar Disorder. | ||
| Medical condition: Bipolar Disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-002551-17 | Sponsor Protocol Number: 12022A | Start Date*: 2007-12-14 | |||||||||||
| Sponsor Name:H. Lundbeck a/s | |||||||||||||
| Full Title: Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo i... | |||||||||||||
| Medical condition: Bipolar Depression at Phase II study with patients. Lu AA34893 is a novel compound under development by H. Lundbeck A/S as an antidepressant. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) AT (Prematurely Ended) FR (Completed) GB (Prematurely Ended) SE (Prematurely Ended) DE (Completed) LT (Prematurely Ended) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
